Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10x Genomics's Ending Cash Position for the quarter that ended in Jun. 2026 was MXN8,768 Mil.
10x Genomics's quarterly Ending Cash Position
increased
from Dec. 2025 (MXN8,534 Mil) to Mar. 2026 (MXN8,841 Mil) but then
declined
from Mar. 2026 (MXN8,841 Mil) to Jun. 2026 (MXN8,768 Mil).
10x Genomics's annual Ending Cash Position
increased
from Dec. 2023 (MXN6,099 Mil) to Dec. 2024 (MXN7,176 Mil) and
increased
from Dec. 2024 (MXN7,176 Mil) to Dec. 2025 (MXN8,534 Mil).
The historical data trend for 10x Genomics's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
10x Genomics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of MXN8,768 Mil mean?
10x Genomics (MEX:TXG) has a Ending Cash Position of MXN8,768 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on 10x Genomics and its competitors.
Is 10x Genomics' Ending Cash Position too high?
10x Genomics' current Ending Cash Position is MXN8,768 Mil. Overall, 10x Genomics has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Ending Cash Position compare to HNGE and WAY?
10x Genomics' Ending Cash Position of MXN8,768 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Healthcare Providers & Services company?
A good Ending Cash Position depends on the Healthcare Providers & Services industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on 10x Genomics and its competitors. 10x Genomics's current Ending Cash Position is MXN8,768 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
10x Genomics (MEX:TXG) has a current Ending Cash Position of MXN8,768 Mil. The stock's GF Value™ is MXN109.97, compared to a current price of MXN335.54 — trading 205.1% above its estimated fair value. The current Ending Cash Position is MXN8,768 Mil. 10x Genomics' overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For 10x Genomics (MEX:TXG), the current Ending Cash Position is MXN8,768 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (MEX:TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of MXN335.54 is trading 205.1% above its estimated GF Value™ of MXN109.97.
Key valuation signals for MEX:TXG:
Ending Cash Position: MXN8,768 Mil
GF Value™: MXN109.97 vs. price of MXN335.54 (205.1% above fair value)
No single metric tells the full story. See the MEX:TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
54GF Score
Get the complete analysis for MEX:TXG
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TXG has been successfully added to your 
